Clinical Trials Browser

Anemia

NCT01284348 2024-08-29

To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer

Classical hematologyGenitourinaryGynecologicHead & NeckThoracic

Anemia, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Small Cell Lung Carcinoma

NCT00931606 2023-09-13

MK-7962-012

Phase 2 Terminated

30 enrolled 32 charts

Classical hematology

Anemia, Neoplasm Metastasis, Neoplasms

NCT03194542 2023-08-24

A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

Phase 2 Completed

95 enrolled 32 charts

Classical hematologyMyeloid

Anemia, Primary Myelofibrosis

NCT01736683 2022-10-24

Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)

Phase 2 Completed

74 enrolled 33 charts

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT04076943 2022-06-03

Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia

Phase 2 Completed

92 enrolled 18 charts

Classical hematology

Anemia

NCT02761642 2018-08-24

A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing Chemotherapy

Phase 2 Completed

200 enrolled 13 charts

Classical hematology

Anemia

NCT01691040 2014-06-26

Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Cancer

Phase 2 Completed

12 enrolled

Classical hematologyLymphoidPlasma cell

Anemia, Lymphoma, Multiple Myeloma, Neoplasms

NCT00401544 2014-01-29

Darbepoetin Alfa With or Without Intravenous (IV) Iron

Phase 2 Completed

243 enrolled 26 charts

Classical hematology

Anemia, Neoplasms

NCT00989092 2014-01-29

Darbepoetin Alfa and Anemia of Cancer

Phase 2 Terminated

287 enrolled 21 charts

Classical hematology

Anemia, Carcinoma, Neoplasms

NCT00386152 2013-07-19

A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy

Phase 2 Terminated

235 enrolled 13 charts

Classical hematology

Anemia, Neoplasms

NCT00144131 2013-05-24

Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy

Phase 2 Completed

750 enrolled

Classical hematology

Anemia, Neoplasms

NCT00035607 2013-05-13

Chemotherapy Related Anemia

Phase 2 Completed

120 enrolled

Classical hematology

Anemia

NCT00111462 2013-05-08

Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy

Phase 2 Completed

Classical hematology

Anemia, Neoplasms

NCT00540696 2013-04-26

Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa

Phase 2 Completed

300 enrolled

Classical hematology

Anemia

NCT00272662 2012-12-21

Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy

Phase 2 Completed

60 enrolled

Classical hematology

Anemia, Neoplasms

NCT00359840 2012-08-31

A Dose Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid Tumor

Phase 2 Completed

120 enrolled

Classical hematology

Anemia

NCT00210600 2011-06-10

Early and Standard Intervention With 120,000 Units of PROCRIT (Epoetin Alfa) Every Three Weeks in Patients Receiving Chemotherapy

Phase 2 Completed

186 enrolled

Classical hematology

Anemia

NCT00210834 2011-06-10

An Efficacy and Safety Study of Epoetin Alfa (PROCRIT) Initiated at 40,000 Units Every Week Versus 80,000 Units Every Two Weeks in Anemic Patients With Cancer Receiving Chemotherapy.

Phase 2 Completed

310 enrolled

Classical hematology

Anemia

NCT00337948 2011-06-10

An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Week or Every Four Weeks

Phase 2 Completed

129 enrolled

Classical hematology

Anemia, Neoplasms

NCT00338416 2011-06-10

An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three Weeks

Phase 2 Completed

115 enrolled

Classical hematology

Anemia, Neoplasms

NCT00269984 2011-06-08

A Study to Determine the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia Caused by Advanced Cancer

Phase 2 Completed

56 enrolled

Classical hematology

Anemia, Neoplasms

NCT00266617 2011-05-18

A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in Patients With Anemia as a Result of Advanced Cancer and Treatment With Aggressive Chemotherapy

Phase 2 Completed

86 enrolled

Classical hematology

Anemia, Neoplasms

NCT00269997 2011-05-18

A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia as a Result of Cancer Treatment With Cisplatin, a Platinum-containing Chemotherapy Drug

Phase 2 Completed

72 enrolled

Classical hematology

Anemia, Neoplasms

NCT00270049 2011-05-18

Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia

Phase 2 Completed

195 enrolled

Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Leukemia, Lymphoid, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00060502 2011-05-17

A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Pancreatic Cancer Related Cachexia

Phase 2 Completed

73 enrolled

Classical hematologyGastrointestinal

Anemia, Anorexia, Cachexia, Pancreatic Neoplasms

NCT00239239 2010-03-05

Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies

Phase 2 Completed

44 enrolled

Classical hematology

Anemia, Neoplasms

NCT00120705 2009-03-25

Treatment for Anemic Subjects With Non-Myeloid Malignancies Receiving Chemotherapy

Phase 2 Completed

204 enrolled

Classical hematology

Anemia, Neoplasms

NCT00095277 2009-03-13

Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer

Phase 2 Completed

220 enrolled

Classical hematologyPlasma cell

Anemia, Neoplasms, Plasma Cell

NCT00120679 2007-12-24

Treatment for Patients With Non-Small Cell Lung Cancer Who Developed Anemia Due to Chemotherapy

Phase 2 Completed

Classical hematologyThoracic

Anemia, Carcinoma, Non-Small-Cell Lung

NCT00120692 2007-12-24

Treatment for Patients Suffering From Anemia Due to Chemotherapy

Phase 2 Completed

BreastClassical hematology

Anemia, Breast Neoplasms

NCT00121030 2007-12-24

Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to Chemotherapy

Phase 2 Completed

Classical hematologyGynecologic

Anemia, Genital Neoplasms, Female, Ovarian Neoplasms, Uterine Neoplasms

Clinical Trials

SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies

To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer

MK-7962-012

A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)

Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia

A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing Chemotherapy

Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Cancer

Darbepoetin Alfa With or Without Intravenous (IV) Iron

Darbepoetin Alfa and Anemia of Cancer

A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy

Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy

Chemotherapy Related Anemia

Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy

Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa

Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy

A Dose Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid Tumor

Early and Standard Intervention With 120,000 Units of PROCRIT (Epoetin Alfa) Every Three Weeks in Patients Receiving Chemotherapy

An Efficacy and Safety Study of Epoetin Alfa (PROCRIT) Initiated at 40,000 Units Every Week Versus 80,000 Units Every Two Weeks in Anemic Patients With Cancer Receiving Chemotherapy.

An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Week or Every Four Weeks

An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three Weeks

A Study to Determine the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia Caused by Advanced Cancer

A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in Patients With Anemia as a Result of Advanced Cancer and Treatment With Aggressive Chemotherapy

A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia as a Result of Cancer Treatment With Cisplatin, a Platinum-containing Chemotherapy Drug

Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia

A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Pancreatic Cancer Related Cachexia

Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies

Treatment for Anemic Subjects With Non-Myeloid Malignancies Receiving Chemotherapy

Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer

Treatment for Patients With Non-Small Cell Lung Cancer Who Developed Anemia Due to Chemotherapy

Treatment for Patients Suffering From Anemia Due to Chemotherapy

Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to Chemotherapy